RxDoctor Payments Data

Gregory Cook, APRN

Nurse Practitioner · Orange Park, FLNPI 1053964395

Payments from drug & device makers

$1,766in general payments, 2019–2025

Across 41 payments — averaging $43.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$791
  • GSK$295
  • Insmed, Inc.$264
  • Boehringer Ingelheim$198
  • Actelion Pharmaceuticals US, Inc.$108
  • Regeneron Healthcare Solutions, Inc.$35
  • plus $74 from 3 others

What the payments were for

  • Food & beverage$1,766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,766 in reported general payments places this provider in the 80th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$55,372
Medicare patients
373
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter119$100,549
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$40,537
Breo ElliptaFluticasone/Vilanterol36$18,374
SymbicortBudesonide/Formoterol Fumarate24$7,323
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$5,858
Albuterol Sulfate HfaAlbuterol Sulfate115$4,410
Incruse ElliptaUmeclidinium Bromide12$4,054
Ventolin HfaAlbuterol Sulfate19$1,246
Wixela InhubFluticasone Propion/Salmeterol12$1,189
Azithromycin60$483
Fluticasone Propionate34$401
Azelastine Hcl16$270
Prednisone62$236
Doxycycline Hyclate14$98
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$295$163,514221 claims
AstraZenecaSymbicort$791$7,32324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Orange Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →